Individuals aged 18 years or older, with CKD-associated osteoporosis
eGFR ≥ 35 mL/min/1.73 m2 and advanced CKD on dialysis
Agree to participate in the research by signing the informed consent form
You may not be if
Individuals under 18 years of age, pregnant or breastfeeding women
Patients with CKD with hypocalcemia/hypophsphatemia
Patients with CKD on dialysis with residual diuresis \> 100 mL/24h\*
Patients with CKD on low-flux membrane dialysis\*
Patients with neoplasia
Hypersensitivity to bisphosphonates, or previous use of the medication
Inadequate oral condition or anticipated invasive dental procedure within the next 12 months
Alkaline phosphatase \< 98 IU/L or \> 180 IU/L\*
PTH \< 130 pg/mL and \> 585 pg/mL\*
CTX \< Lower Limit of Normal (LLN) or
CTX \< Upper Reference Limit (URL)\*
Severe liver disease
Severe heart disease
Clinical suspiction of osteomalacia or adynamic bone disease
Cytopenias, defined as: platelets \< 120,000/mm³, neutrophils \< 3,000/mm³, lymphocytes \< 1,000/mm³ and hematocrit \< 26% \* Applicable only to the group of patients undergoing dialysis.
Clareo Health | Pharmacokinetics of Zoledronic Acid in Patients on Dialysis
